Novo partners with Orbis, deepening investment in oral peptide drugs

PartnershipMacrocyclesPositive

AI Analysis

Summary

Novo and Orbis announced a potential $1.4 billion partnership to collaborate on oral peptide drug candidates (macrocycles) for treating cardiometabolic diseases.

Outcome Details

Potential $1.4 billion alliance to collaborate on oral peptide drugs (macrocycles) for cardiometabolic diseases

Importance:7/10

Sentiment:

0.60

PartnershipOral peptidesMacrocyclesCardiometabolicDrug development

Related Companies

$DMIIR

Read the original article

Published by BioPharma Dive on September 17, 2026 3:55 PM

Read Original